These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 9774952)

  • 1. Pyrazoloacridine for the treatment of hormone-refractory prostate cancer.
    Small EJ; Fippin LJ; Whisenant SP
    Cancer Invest; 1998; 16(7):456-61. PubMed ID: 9774952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter phase II trial of losoxantrone (DuP-941) in hormone-refractory metastatic prostate cancer.
    Huan SD; Natale RB; Stewart DJ; Sartiano GP; Stella PJ; Roberts JD; Symes AL; Finizio M
    Clin Cancer Res; 2000 Apr; 6(4):1333-6. PubMed ID: 10778959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective randomized Phase II trial of pegylated doxorubicin in the management of symptomatic hormone-refractory prostate carcinoma.
    Heidenreich A; Sommer F; Ohlmann CH; Schrader AJ; Olbert P; Goecke J; Engelmann UH
    Cancer; 2004 Sep; 101(5):948-56. PubMed ID: 15329902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor.
    Small EJ; Reese DM; Um B; Whisenant S; Dixon SC; Figg WD
    Clin Cancer Res; 1999 Jul; 5(7):1738-44. PubMed ID: 10430077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy.
    Pruthi RS; Derksen JE; Moore D; Carson CC; Grigson G; Watkins C; Wallen E
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2172-7. PubMed ID: 16609031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer.
    Rago RP; Einstein A; Lush R; Beer TM; Ko YJ; Henner WD; Bubley G; Merica EA; Garg V; Ette E; Harding MW; Dalton WS
    Cancer Chemother Pharmacol; 2003 Apr; 51(4):297-305. PubMed ID: 12721757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer.
    Lin CC; Hsu CH; Chen J; Tsai TC; Cheng AL; Pu YS
    Anticancer Res; 2001; 21(2B):1385-90. PubMed ID: 11396219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.
    Hussain M; Tangen CM; Lara PN; Vaishampayan UN; Petrylak DP; Colevas AD; Sakr WA; Crawford ED;
    J Clin Oncol; 2005 Dec; 23(34):8724-9. PubMed ID: 16314632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
    Miyake H; Hara I; Eto H
    BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcome of oral uracil/tegafur (UFT) therapy for patients with hormone refractory prostate cancer.
    Miyake H; Hara I; Yamazaki H; Eto H
    Oncol Rep; 2005 Sep; 14(3):673-6. PubMed ID: 16077973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
    James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA
    Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma.
    Vogelzang NJ; Karrison T; Stadler WM; Garcia J; Cohn H; Kugler J; Troeger T; Giannone L; Arrieta R; Ratain MJ; Vokes EE
    Cancer; 2004 Jan; 100(1):65-71. PubMed ID: 14692025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study.
    Plaxe SC; Blessing JA; Bookman MA; Creasman WT
    Gynecol Oncol; 2002 Jan; 84(1):32-5. PubMed ID: 11748972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum PSA half-life as a predictor of survival for hormone-refractory prostate cancer patients: modelization using a standardized set of response criteria.
    Banu E; Banu A; Medioni J; Levy E; Thiounn N; Mejean A; Andrieu JM; Oudard S
    Prostate; 2007 Oct; 67(14):1543-9. PubMed ID: 17705243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lycopene: a novel drug therapy in hormone refractory metastatic prostate cancer.
    Ansari MS; Gupta NP
    Urol Oncol; 2004; 22(5):415-20. PubMed ID: 15464923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901.
    Amin A; Halabi S; Gelmann EP; Stadler W; Vogelzang N; Small E
    Urol Oncol; 2004; 22(5):398-403. PubMed ID: 15464920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticancer effect of combination therapy of VP16 and fosfesterol in hormone-refractory prostate cancer.
    Azuma H; Sakamoto T; Kiyama S; Ubai T; Kotake Y; Inamoto T; Takahara K; Nishimura Y; Segawa N; Katsuoka Y
    Am J Clin Oncol; 2008 Apr; 31(2):188-94. PubMed ID: 18391605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer.
    Montgomery RB; Nelson PS; Lin D; Ryan CW; Garzotto M; Beer TM
    Cancer; 2007 Sep; 110(5):996-1002. PubMed ID: 17639587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of response to carboplatin in patients with hormone-refractory prostate cancer: a critical analysis of drug activity.
    Miglietta L; Cannobbio L; Boccardo F
    Anticancer Res; 1995; 15(6B):2825-8. PubMed ID: 8669872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
    Lee AK; Levy LB; Cheung R; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.